SPDR S&P Biotech ETF Rating $140.18 -3.94 (-2.73%) Closing price 11/20/2026 04:10 PM EasternExtended Trading$140.94 +0.76 (+0.54%) As of 11/20/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsNews and TrendsOwnershipRatingsShort Interest SPDR S&P Biotech ETF Aggregate Rating and Price Target (2026)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.XBI Aggregate RatingModerate Buy 2.67Holdings in XBI have an aggregate rating of Moderate Buy based on 512 analyst ratings issued in the past year covering 25 companies (40.2% of the portfolio).XBI Aggregate Price Target$140.18High Prediction$140.18Average Prediction$140.18Low Prediction$140.18Holdings in XBI have an aggregate price target of $140.18 and a range of $140.18 to $140.18 covering 25 companies (40.2% of the portfolio).XBI Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy0 Buy rating(s)Moderate Buy19 Moderate Buy rating(s)Hold6 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by SPDR S&P Biotech ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 25 XBI Holdings ExportWeight In ETFCompanyShare PriceConsensus RatingConsensus Price TargetPossible UpsideNumber of RatingsMarketRank™Indicator(s)ViewRatings2.66%MRNAModerna$194.18-2.6%Hold$120.25 -38.1%251.3548 of 5 starsTrending NewsAnalyst ForecastInsider Trade1.78%SYRESpyre Therapeutics$93.47-4.3%Moderate Buy$110.53 18.3%172.1943 of 5 stars1.76%EXELExelixis$64.63-1.8%Hold$58.62 -9.3%172.1898 of 5 stars1.74%BIIBBiogen$249.59+1.0%Moderate Buy$255.45 2.3%332.9174 of 5 starsTrending NewsAnalyst ForecastOptions Volume1.74%TGTXTG Therapeutics$63.34-2.4%Moderate Buy$63.00 -0.5%92.0382 of 5 starsAnalyst Downgrade1.73%AMGNAmgen$435.52-0.8%Hold$428.62 -1.6%333.9086 of 5 starsAnalyst ForecastAnalyst Revision1.72%REGNRegeneron Pharmaceuticals$920.69-0.3%Moderate Buy$904.41 -1.8%313.7636 of 5 starsTrending NewsAnalyst ForecastInsider Trade1.70%ORKAOruka Therapeutics$95.81-1.8%Moderate Buy$141.00 47.2%112.7177 of 5 starsAnalyst Forecast1.70%UTHRUnited Therapeutics$554.73-0.8%Moderate Buy$676.40 21.9%164.6432 of 5 starsTrending NewsInsider Trade1.70%ABBVAbbVie$286.19+0.9%Moderate Buy$299.62 4.7%293.763 of 5 starsTrending NewsAnalyst ForecastAnalyst Revision1.69%GILDGilead Sciences$166.33-0.1%Moderate Buy$171.63 3.2%293.1904 of 5 starsAnalyst ForecastInsider TradeAnalyst Revision1.63%NBIXNeurocrine Biosciences$150.57-3.8%Moderate Buy$202.59 34.5%244.8901 of 5 stars1.53%ALKSAlkermes$44.94-2.7%Moderate Buy$55.73 24.0%172.2698 of 5 starsAnalyst Downgrade1.52%BBIOBridgeBio Pharma$76.03-2.8%Moderate Buy$104.42 37.3%222.836 of 5 starsInsider Trade1.52%VRTXVertex Pharmaceuticals$514.76-1.1%Moderate Buy$596.44 15.9%283.8149 of 5 starsInsider Trade1.45%PRAXPraxis Precision Medicines$300.43-3.4%Moderate Buy$660.50 119.9%223.1666 of 5 starsNews CoverageAnalyst Upgrade1.45%ROIVRoivant Sciences$38.60-0.9%Moderate Buy$46.82 21.3%142.5918 of 5 starsTrending NewsAnalyst ForecastInsider TradeAnalyst Revision1.42%KYMRKymera Therapeutics$115.10-3.6%Moderate Buy$139.16 20.9%272.4423 of 5 stars1.42%TWSTTwist Bioscience$103.23-7.5%Hold$133.92 29.7%122.6002 of 5 starsGap Down1.41%INCYIncyte$114.63-1.1%Hold$134.38 17.2%253.3159 of 5 starsAnalyst ForecastInsider Trade1.40%NTRANatera$273.08-5.8%Moderate Buy$396.93 45.4%232.8659 of 5 starsAnalyst Forecast1.39%PTCTPTC Therapeutics$56.42-3.3%Moderate Buy$99.23 75.9%153.7876 of 5 starsInsider Trade1.38%ERASErasca$13.61-4.3%Moderate Buy$23.17 70.2%121.7184 of 5 starsTrending NewsAnalyst ForecastAnalyst RevisionHigh Trading Volume1.37%KODKodiak Sciences$97.17-0.7%Moderate Buy$117.86 21.3%82.8881 of 5 starsAnalyst ForecastAnalyst Revision1.37%HALOHalozyme Therapeutics$91.35-1.8%Hold$110.17 20.6%134.5201 of 5 starsTrending NewsAnalyst ForecastInsider Trade This page (NYSEARCA:XBI) was last updated on 11/21/2026 by MarketBeat.com Staff. From Our PartnersSeven bucks, yours for life: my Black Friday indicator dealBase Camp Trading's Thomas Wood is giving away his proprietary Snapback Indicator for just $7 this Black Frida...Base Camp Trading | SponsoredYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredElon masterplan could turn $500 into half a millionJeff Brown called Tesla an AI company in 2018, when Wall Street said it was going bankrupt. The stock has been...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SPDR S&P Biotech ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share SPDR S&P Biotech ETF With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.